問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

Division of Nuclear Medicine

更新時間:2023-09-19

謝德鈞
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

26Cases

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Infusion fluid Infusion fluid Tablets

Participate Sites
5Sites

Recruiting5Sites

2020-10-26 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2019-07-22 - 2026-12-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-01-01 - 2029-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2017-06-01 - 2021-01-06

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated7Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-06-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-10-01 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-02-01 - 2020-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting3Sites

Terminated6Sites

2021-08-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3